Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

A proviral derivative from a reference attenuated EIAV vaccine strain failed to elicit protective immunity.

Ma J, Shi N, Jiang CG, Lin YZ, Wang XF, Wang S, Lv XL, Zhao LP, Shao YM, Kong XG, Zhou JH, Shen RX.

Virology. 2011 Feb 5;410(1):96-106. doi: 10.1016/j.virol.2010.10.032. Epub 2010 Nov 20.

2.

Genomic comparison between attenuated Chinese equine infectious anemia virus vaccine strains and their parental virulent strains.

Wang X, Wang S, Lin Y, Jiang C, Ma J, Zhao L, Lv X, Wang F, Shen R, Kong X, Zhou J.

Arch Virol. 2011 Feb;156(2):353-7. doi: 10.1007/s00705-010-0877-8. Epub 2010 Dec 7.

PMID:
21136127
3.

Envelope determinants of equine lentiviral vaccine protection.

Craigo JK, Ezzelarab C, Cook SJ, Chong L, Horohov D, Issel CJ, Montelaro RC.

PLoS One. 2013 Jun 13;8(6):e66093. doi: 10.1371/journal.pone.0066093. Print 2013.

4.

An attenuated EIAV vaccine strain induces significantly different immune responses from its pathogenic parental strain although with similar in vivo replication pattern.

Lin YZ, Shen RX, Zhu ZY, Deng XL, Cao XZ, Wang XF, Ma J, Jiang CG, Zhao LP, Lv XL, Shao YM, Zhou JH.

Antiviral Res. 2011 Nov;92(2):292-304. doi: 10.1016/j.antiviral.2011.08.016. Epub 2011 Aug 25.

PMID:
21893100
5.

Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy.

Craigo JK, Li F, Steckbeck JD, Durkin S, Howe L, Cook SJ, Issel C, Montelaro RC.

J Virol. 2005 Mar;79(5):2666-77.

6.

In vivo evolution of the gp90 gene and consistently low plasma viral load during transient immune suppression demonstrate the safety of an attenuated equine infectious anemia virus (EIAV) vaccine.

Ma J, Jiang C, Lin Y, Wang X, Zhao L, Xiang W, Shao Y, Shen R, Kong X, Zhou J.

Arch Virol. 2009;154(5):867-73. doi: 10.1007/s00705-009-0378-9. Epub 2009 Apr 12.

PMID:
19363668
7.
8.

C-terminal truncation of the transmembrane protein of an attenuated lentiviral vaccine alters its in vitro but not in vivo replication and weakens its potential pathogenicity.

Jiang CG, Gao X, Ma J, Lin YZ, Wang XF, Zhao LP, Hua YP, Liu D, Zhou JH.

Virus Res. 2011 Jun;158(1-2):235-45. doi: 10.1016/j.virusres.2011.04.007. Epub 2011 Apr 22.

PMID:
21539871
9.

A pilot study on an attenuated Chinese EIAV vaccine inducing broadly neutralizing antibodies.

Meng Q, Lin Y, Ma J, Ma Y, Zhao L, Li S, Liang H, Zhou J, Shen R, Zhang X, Shao Y.

Arch Virol. 2011 Aug;156(8):1455-62. doi: 10.1007/s00705-011-0992-1. Epub 2011 Apr 17.

PMID:
21499906
10.

Correlation between the induction of Th1 cytokines by an attenuated equine infectious anemia virus vaccine and protection against disease progression.

Zhang X, Wang Y, Liang H, Wei L, Xiang W, Shen R, Shao Y.

J Gen Virol. 2007 Mar;88(Pt 3):998-1004.

PMID:
17325374
11.
12.

Long terminal repeats are not the sole determinants of virulence for equine infectious anemia virus.

Tu YB, Zhou T, Yuan XF, Qiu HJ, Xue F, Sun CQ, Wang L, Wu DL, Peng JM, Kong XG, Tong GZ.

Arch Virol. 2007 Jan;152(1):209-18. Epub 2006 Aug 24.

PMID:
16932982
13.

Reverse mutation of the virulence-associated S2 gene does not cause an attenuated equine infectious anemia virus strain to revert to pathogenicity.

Gao X, Jiang CG, Wang XF, Lin YZ, Ma J, Han XE, Zhao LP, Shen RX, Xiang WH, Zhou JH.

Virology. 2013 Sep 1;443(2):321-8. doi: 10.1016/j.virol.2013.05.017. Epub 2013 Jun 12.

14.

Envelope-specific T-helper and cytotoxic T-lymphocyte responses associated with protective immunity to equine infectious anemia virus.

Tagmyer TL, Craigo JK, Cook SJ, Issel CJ, Montelaro RC.

J Gen Virol. 2007 Apr;88(Pt 4):1324-36.

PMID:
17374779
17.

Protective efficacy of centralized and polyvalent envelope immunogens in an attenuated equine lentivirus vaccine.

Craigo JK, Ezzelarab C, Cook SJ, Liu C, Horohov D, Issel CJ, Montelaro RC.

PLoS Pathog. 2015 Jan 8;11(1):e1004610. doi: 10.1371/journal.ppat.1004610. eCollection 2015 Jan.

18.

Amino acid mutations of the infectious clone from Chinese EIAV attenuated vaccine resulted in reversion of virulence.

Shen T, Liang H, Tong X, Fan X, He X, Ma Y, Xiang W, Shen R, Zhang X, Shao Y.

Vaccine. 2006 Feb 6;24(6):738-49. Epub 2005 Sep 15.

PMID:
16202485
19.

Combined amino acid mutations occurring in the envelope closely correlate with pathogenicity of EIAV.

Liang H, He X, Shen RX, Shen T, Tong X, Ma Y, Xiang WH, Zhang XY, Shao YM.

Arch Virol. 2006 Jul;151(7):1387-403. Epub 2006 Feb 26.

PMID:
16502285
20.

A pilot study comparing the development of EIAV Env-specific antibodies induced by DNA/recombinant vaccinia-vectored vaccines and an attenuated Chinese EIAV vaccine.

Meng Q, Lin Y, Ma J, Ma Y, Zhao L, Li S, Yang K, Zhou J, Shen R, Zhang X, Shao Y.

Viral Immunol. 2012 Dec;25(6):477-84. doi: 10.1089/vim.2012.0014. Epub 2012 Nov 21.

Supplemental Content

Support Center